{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:44:04Z","timestamp":1788957844075,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.drugpo.2019.07.006","type":"journal-article","created":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T16:52:21Z","timestamp":1563641541000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States"],"prefix":"10.1016","volume":"73","author":[{"given":"Corey S.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek H.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.drugpo.2019.07.006_bib0005","first-page":"CD004147","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence","author":"Amato","year":"2011","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","article-title":"Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington","volume":"93","author":"Amiri","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0015","series-title":"Changes in the supply of physicians with a DEA DATA waiver to prescribe buprenorphine for opioid use disorder, Data Brief #162","author":"Andrilla","year":"2017"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/AJP.0000000000000011","article-title":"Trends and regional variation in opioid overdose mortality among Veterans Health Administration patients, fiscal year 2001\u20132009","volume":"30","author":"Bohnert","year":"2014","journal-title":"The Clinical Journal of Pain"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0025","series-title":"Medication-assisted treatment","author":"Bureau of Justice Assistance","year":"2018"},{"issue":"6","key":"10.1016\/j.drugpo.2019.07.006_bib0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s11606-018-4801-3","article-title":"Methadone matters: What the United States can learn from the global effort to treat opioid addiction","volume":"34","author":"Calcaterra","year":"2019","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13722-019-0149-1","article-title":"Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco","volume":"14","author":"Carter","year":"2019","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0040","series-title":"Memorandum and order, civil action No. 18-11972-DJC","author":"Casper","year":"2018"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drugalcdep.2018.04.012","article-title":"Exploring opioid use disorder, its impact, and treatment among individuals experiencing homelessness as part of a family","volume":"188","author":"Chatterjee","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0050","series-title":"The Mayor\u2019s task force to combat the opioid epidemic in Philadelphia: Final report and recommendations","author":"City of Philadelphia","year":"2017"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11090","article-title":"Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.drugpo.2018.06.015","article-title":"Stigma and the public health agenda for the opioid crisis in America","volume":"59","author":"Corrigan","year":"2018","journal-title":"The International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0070","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1377\/hlthaff.2016.0098","article-title":"Access to mental health care increased but not for substance use, while disparities remain","volume":"35","author":"Creedon","year":"2016","journal-title":"Health Affairs (Millwood)"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0075","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMp1811988","article-title":"Emergency departments \u2013 A 24\/7\/365 option for combating the opioid crisis","volume":"379","author":"D\u2019Onofrio","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0080","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","article-title":"Opioid crisis: No easy fix to its social and economic determinants","volume":"108","author":"Dasgupta","year":"2017","journal-title":"American Journal of Public Health"},{"issue":"1","key":"10.1016\/j.drugpo.2019.07.006_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJMp1813961","article-title":"The SUPPORT for Patients and Communities Act \u2013 What will it mean for the opioid-overdose crisis?","volume":"380","author":"Davis","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.10.013","article-title":"Legal changes to increase access to naloxone for opioid overdose reversal in the United States","volume":"157","author":"Davis","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.drugalcdep.2016.04.002","article-title":"Physician continuing education to reduce opioid misuse, abuse, and overdose: Many opportunities, few requirements","volume":"163","author":"Davis","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0100","doi-asserted-by":"crossref","DOI":"10.18060\/3911.0027","article-title":"The law and policy of opioids for pain management, addiction treatment, and overdose reversal","volume":"14","author":"Davis","year":"2017","journal-title":"Indiana Health Law Review"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0105","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1377\/hlthaff.2014.1205","article-title":"Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002\u201311","volume":"34","author":"Dick","year":"2015","journal-title":"Health Affairs (Millwood)"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1331\/JAPhA.2015.14177","article-title":"Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients","volume":"55","author":"DiPaula","year":"2015","journal-title":"Journal of the American Pharmacists Association: JAPhA (2003)"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0115","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A medical treatment for diacetylmorphine (Heroin) addiction. A clinical trial with methadone hydrochloride","volume":"193","author":"Dole","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0120","series-title":"Use of telemedicine while providing medication assisted treatment (MAT)","author":"Drug Enforcement Administration","year":"2018"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0125","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s11606-010-1377-y","article-title":"The Physician Clinical Support System-Buprenorphine (PCSS-B): A novel project to expand\/improve buprenorphine treatment","volume":"25","author":"Egan","year":"2010","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0130","series-title":"Mayor Mark Farrell announces innovative program to fight opioid crisis on San Francisco Streets","author":"Farrell","year":"2018"},{"issue":"3","key":"10.1016\/j.drugpo.2019.07.006_bib0135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","article-title":"Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver","volume":"76","author":"Fiscella","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.drugpo.2018.01.001","article-title":"Post opioid overdose outreach by public health and public safety agencies: Exploration of emerging programs in Massachusetts","volume":"54","author":"Formica","year":"2018","journal-title":"The International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0145","unstructured":"Ga. Stat. \u00a7 26-5-48(b)."},{"key":"10.1016\/j.drugpo.2019.07.006_bib0150","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","article-title":"Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system","volume":"75","author":"Green","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0155","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.2105\/AJPH.2011.300595","article-title":"Life after the ban: An assessment of US syringe exchange programs\u2019 attitudes about and early experiences with federal funding","volume":"102","author":"Green","year":"2012","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0160","unstructured":"H.R. 2482 (116th Congress): Mainstreaming Addiction Treatment Act of 2019."},{"key":"10.1016\/j.drugpo.2019.07.006_bib0165","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","article-title":"Policy pathways to address provider workforce barriers to buprenorphine treatment","volume":"54","author":"Haffajee","year":"2018","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren\u2019t physicians prescribing more buprenorphine?","volume":"78","author":"Huhn","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0175","unstructured":"440 Ind. Admin. Code 10-2-3(a)(5)."},{"key":"10.1016\/j.drugpo.2019.07.006_bib0180","first-page":"e1","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0185","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study","volume":"2","author":"Kimber","year":"2015","journal-title":"The Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.drugpo.2019.07.006_bib0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0195","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","article-title":"Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS","volume":"103","author":"Lawrinson","year":"2008","journal-title":"Addiction"},{"issue":"21","key":"10.1016\/j.drugpo.2019.07.006_bib0200","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1001\/jama.2019.5523","article-title":"Medication-based treatment to address opioid use disorder","volume":"321","author":"Leshner","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0205","series-title":"Medicaid and the criminal justice system","author":"MACPAC","year":"2018"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0210","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addbeh.2018.03.014","article-title":"Opioid-overdose laws association with opioid use and overdose mortality","volume":"86","author":"McClellan","year":"2018","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0215","series-title":"Comprehensive update on state medicaid coverage of MedicationAssisted treatments and substance use disorder services","author":"Miller","year":"2018"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12954-017-0157-y","article-title":"Two steps forward, one step back: Current harm reduction policy and politics in the United States","volume":"14","author":"Nadelmann","year":"2017","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0225","unstructured":"National Center for Health Statistics. Vital Statistics Rapid Release: Provisional Drug Overdose Death Counts. Retrieved September 1, 2018 from https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"key":"10.1016\/j.drugpo.2019.07.006_bib0230","series-title":"Fair chance licensing reform: Opening pathways for people with records to join licensed professions","author":"National Employment Law Project","year":"2018"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0235","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jama.2014.2147","article-title":"Confronting the stigma of opioid use disorder\u2013and its treatment","volume":"311","author":"Olsen","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0240","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2105\/AJPH.2018.304514","article-title":"Opioid overdose mortality among former North Carolina inmates: 2000\u20132015","volume":"108","author":"Ranapurwala","year":"2018","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0245","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/948789","article-title":"Distance traveled and cross-state commuting to opioid treatment programs in the United States","volume":"2011","author":"Rosenblum","year":"2011","journal-title":"Journal of Environmental and Public Health"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0250","series-title":"The hill","article-title":"HHS chief pitches new measures to expand opioid addiction treatment","author":"Roubein","year":"2018"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0255","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2015.10345","article-title":"Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004\u20132013","volume":"314","author":"Saloner","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0260","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMp1803982","article-title":"Methadone in primary care - one small step for congress, one giant leap for addiction treatment","volume":"379","author":"Samet","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0265","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","article-title":"Access to treatment for opioid dependence in rural America: Challenges and future directions","volume":"71","author":"Sigmon","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0270","unstructured":"MX Group, Inc. v. City of Covington, 293 F.3d 326 (6th Cir. 2002)."},{"key":"10.1016\/j.drugpo.2019.07.006_bib0275","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0280","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/jama.2016.10542","article-title":"Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment","volume":"316","author":"Stein","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0285","series-title":"Key substance use and mental health indicators in the United States: Results from the 2016 national survey on drug use and health","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0290","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s10900-013-9681-1","article-title":"Traveling towards disease: Transportation barriers to health care access","volume":"38","author":"Syed","year":"2013","journal-title":"Journal of Community Health"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0295","series-title":"New directions treatment servs. v. City of reading, 490 F.3D 293","author":"Third Circuit","year":"2007"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0300","series-title":"Letter to Alex Azar","author":"Twenty-two State Health Directors","year":"2019"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0305","series-title":"Telemedicine and prescribing buprenorphine for the treatment of opioid use disorder","author":"U.S. Department of Health and Human Services","year":"2018"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0310","series-title":"21 U.S.C. \u00a7 823(g)","author":"United States Code","year":"2019"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0315","series-title":"21 U.S.C. \u00a7 823(g)(2)(B)","author":"United States Code","year":"2019"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0320","series-title":"21 U.S.C. \u00a7 823(g)(2)(G)","author":"United States Code","year":"2019"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0325","series-title":"42 C.F.R. \u00a7 8.11(a)","author":"United States Code","year":"2019"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0330","series-title":"42 C.F.R. \u00a7 8.12(e)","author":"United States Code","year":"2019"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0335","series-title":"42 C.F.R. \u00a7 8.12(h)(3)","author":"United States Code","year":"2019"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0340","series-title":"42 C.F.R. \u00a7 8.12(i)","author":"United States Code","year":"2019"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0345","series-title":"42 C.F.R. \u00a7\u00a7 8.12(f)","author":"United States Code","year":"2019"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0350","series-title":"Federal ban on methadone vans seen as barrier to treatment","author":"Vestal","year":"2018"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0355","series-title":"An evaluation report prepared for the Virginia department of medical assistance services addiction and recovery treatment services: Access and utilization during the first year (April 2017\u2013March 2018)","author":"Virginia Commonwealth University","year":"2018"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0360","doi-asserted-by":"crossref","first-page":"279","DOI":"10.15585\/mmwr.mm6709e1","article-title":"Vital signs: Trends in emergency department visits for suspected opioid overdoses - United States, July 2016\u2013September 2017","volume":"67","author":"Vivolo-Kantor","year":"2018","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0365","unstructured":"W. Va. Code Ann. \u00a7 16-5Y-12."},{"key":"10.1016\/j.drugpo.2019.07.006_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1802741","article-title":"Primary care and the opioid-overdose crisis - buprenorphine myths and realities","volume":"379","author":"Wakeman","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0375","unstructured":"Wash. Rev. Code Ann. \u00a7 71.24.590(1)(b)."},{"key":"10.1016\/j.drugpo.2019.07.006_bib0380","article-title":"Bridging the barriers: Public health strategies for expanding drug treatment in communities","volume":"57","author":"Weber","year":"2005","journal-title":"Rutgers Law Review"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0385","series-title":"Negro cocaine \"Fiends\" are a new southern menace","author":"Williams","year":"1914"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0390","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s11524-010-9451-7","article-title":"Impact of interim methadone maintenance on HIV risk behaviors","volume":"87","author":"Wilson","year":"2010","journal-title":"Journal of Urban Health"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0395","first-page":"1","article-title":"The case for a medication first approach to the treatment of opioid use disorder","author":"Winograd","year":"2019","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.drugpo.2019.07.006_bib0400","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.mayocp.2018.07.001","article-title":"Telemedicine\u2019s role in addressing the opioid epidemic. Mayo clinic proceedings","volume":"93","author":"Yang","year":"2018","journal-title":"Mayo Clinic"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:43:56Z","timestamp":1760629436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395919301847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":80,"alternative-id":["S0955395919301847"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.07.006","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}